- Home
- ENTA vs BANX Comparison
ENTA vs BANX Comparison
Compare ENTA & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- BANX
- Stock Information
- Founded
- ENTA 1995
- BANX 2013
- Country
- ENTA United States
- BANX United States
- Employees
- ENTA N/A
- BANX N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- BANX Trusts Except Educational Religious and Charitable
- Sector
- ENTA Health Care
- BANX Finance
- Exchange
- ENTA Nasdaq
- BANX Nasdaq
- Market Cap
- ENTA 164.6M
- BANX 146.9M
- IPO Year
- ENTA 2013
- BANX N/A
- Fundamental
- Price
- ENTA $11.81
- BANX $21.93
- Analyst Decision
- ENTA Strong Buy
- BANX
- Analyst Count
- ENTA 5
- BANX 0
- Target Price
- ENTA $20.20
- BANX N/A
- AVG Volume (30 Days)
- ENTA 1.1M
- BANX 23.4K
- Earning Date
- ENTA 08-11-2025
- BANX 06-17-2025
- Dividend Yield
- ENTA N/A
- BANX 9.66%
- EPS Growth
- ENTA N/A
- BANX N/A
- EPS
- ENTA N/A
- BANX 2.35
- Revenue
- ENTA $64,806,000.00
- BANX $29,467,794.00
- Revenue This Year
- ENTA N/A
- BANX N/A
- Revenue Next Year
- ENTA $1.65
- BANX N/A
- P/E Ratio
- ENTA N/A
- BANX $8.88
- Revenue Growth
- ENTA N/A
- BANX 2.73
- 52 Week Low
- ENTA $4.09
- BANX $17.99
- 52 Week High
- ENTA $15.28
- BANX $21.67
- Technical
- Relative Strength Index (RSI)
- ENTA 61.09
- BANX 56.94
- Support Level
- ENTA $7.05
- BANX $22.00
- Resistance Level
- ENTA $15.34
- BANX $22.34
- Average True Range (ATR)
- ENTA 1.32
- BANX 0.49
- MACD
- ENTA 0.47
- BANX -0.03
- Stochastic Oscillator
- ENTA 53.86
- BANX 27.20
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.